On Monday, ReneSola Ltd. (ADR) (NYSE:SOL)’s shares inclined 13.45% to $1.35.
ReneSola Ltd (SOL), a leading brand and technology provider of energy-efficient products, declared that during the third quarter of 2015, the Company repurchased $36.0 million notional amount of its convertible notes due on March 15, 2018 with a put option on March 15, 2016. The Company has about $26.1 million in convertible bonds outstanding. During the third quarter, the Company also repurchased about 807,000 American depositary shares following its declarement on September 23, 2015 of the authorization by its Board of Directors of a share repurchase program of up to US$20 million in aggregate value of its outstanding ADSs within the next 12 months.
The Company might continue to repurchase its convertible bonds and American depositary shares from time to time, subject to market conditions and other planned considerations. Such purchases will be made in accordance with the applicable laws and subject to any required regulatory approvals.
ReneSola Ltd, through its auxiliaries, manufactures and sells various solar power products. It operates through two segments, Wafer, and Cell and Module.
Delphi Automotive PLC (NYSE:DLPH)’s shares gained 0.83% to $78.63.
Delphi Automotive PLC (DLPH) will release its third quarter 2015 financial results on Oct. 29 and will hold an investor call the same day at 8:30 a.m. (ET). The call will be hosted by Delphi’s President and Chief Executive Officer, Kevin Clark, and Chief Financial Officer, Mark Murphy.
Delphi Automotive PLC, together with its auxiliaries, manufacturers vehicle components; and provides electrical and electronic, powertrain, safety, and thermal technology solutions to the automotive and commercial vehicle markets worldwide.
At the end of Monday’s trade, The Medicines Company (NASDAQ:MDCO)‘s shares surged -1.87% to $38.29.
The Medicines Company declared that it will make four presentations on its infectious disease programs at IDWeek between October 7 – 11 in San Diego, CA.
Company researchers will report on research investigating geographical differences in clinical outcomes for patients with carbapenem-resistant Enterobacteriaceae (CRE). The Centers for Disease Control (CDC) consider CRE to be one of the three most urgent antimicrobial resistant infectious disease threats. Two other posters will contribute data on dosing and nonclinical efficacy, and the in vitro activity of CARBAVANCE® (meropenem/RPX7009), an investigational agent that is presently in phase 3 clinical trials.
The fourth presentation will report data from a contemporary analysis of the in vitro activity of ORBACTIV® (oritavancin) for injection and competitive agents against Staphylococcus aureus (SA), counting methicillin-resistant Staphylococcus aureus (MRSA), responsible for invasive community-associated and hospital-associated infections among patients with acute bacterial skin and skin structure infections (ABSSSI) in the US.
The Medicines Company provides medicines for patients in acute and intensive care hospitals worldwide. Its development stage products comprise Cangrelor for the prevention of platelet activation and aggregation; IONSYS for the short-term administration of acute postoperative pain; Raplixa, a dry powder topical formulation of fibrogen and thrombin; and RPX-602 for the treatment of bacterial infections.
NewLink Genetics Corp (NASDAQ:NLNK), ended its Monday’s trading session with 0.33% gain, and closed at $36.48.
NewLink Genetics Corporation (NLNK) declared that the Biomedical Advanced Research and Development Authority (BARDA) of the United States Department of Health and Human Services (HHS) has exercised an $18 million option on NewLink Genetics’ existing contract to support the scale-up of the manufacturing process regarding its investigational rVSV-ZEBOV GP (Ebola) vaccine candidate. BARDA made an initial $30 million contract award to NewLink in late 2014 and is now providing additional funding to continue development of the Ebola vaccine candidate. Merck (MRK), known as MSD outside the United States and Canada, has the license for research, development, manufacturing and commercialization of the rVSV-ZEBOV GP (Ebola) vaccine.
The rVSV-ZEBOV GP (Ebola) vaccine candidate was originally developed by the Public Health Agency of Canada (PHAC) and was subsequently licensed to a partner of NewLink Genetics. In late 2014, Merck licensed the vaccine from NewLink Genetics to apply Merck’s vaccine expertise to assist accelerate the development of this vaccine candidate. Clinical studies of the vaccine candidate are ongoing.
NewLink Genetics Corporation, a biopharmaceutical company, focuses on discovering, developing, and commercializing immunotherapeutic products to enhance treatment options for patients with cancer.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
